Ameridose Compounding Pharmacy Drug Recall: Sterility Concerns

Federal health experts warn that the same dangerous conditions that led to a nationwide fungal meningitis outbreak were present at a second compounding pharmacy, which is now recalling all of its injection drugs. 

An Ameridose drug recall was announced by the FDA on October 31, indicating that preliminary findings of an inspection have raised concerns about a lack of sterility assurance for products produced and distributed by the facility. As a result all unexpired Ameridose drugs have been recalled.

Ameridose is a Massachusetts compounding pharmacy that is owned by the same principals that own the New England Compounding Center (NECC), whose recalled epidural steroid injections have been linked to a fungal meningitis outbreak that has killed 28 people and sickened nearly 400.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

FDA investigators are in the process of inspecting Ameridose’s facilities, but warn that sterility problems at the facility could represent a serious health risk for consumers.

Investigators believe that sterility problems led to NECC distributing more than 17,000 vials of tainted steroid injections, and the U.S. Centers for Disease Control and Prevention (CDC) warns that an estimated 14,000 people who received those injections may be at risk for fungal meningitis or other infections.

FDA officials said that while Ameridose is recalling all of its products that have not expired and doctors should not use any they have in stock, at this stage there is no sign that the drugs are contaminated. Therefore, doctors are not being advised to follow up with patients who received Ameridose drugs.

There are some concerns, however, that the shut downs may lead to a drug shortage. The FDA warns that some of the drugs linked to the Ameridose recall were on the critical drug shortage list already.

“The FDA’s top priority is to ensure that drugs are safe for the American public,” said FDA Commissioner Margaret A. Hamburg, M.D. “The agency is taking all steps within its authority to help prevent or alleviate shortage situations and to minimize the impact this recall may have on drug supplies.”

Doctors and patients with questions can contact the FDA’s Drug Information Line at (855) 543-DRUG (3784) and can press * to get information on the Ameridose recall.

Ameridose drugs can be identified by the company logo or its name. A complete list of Ameridose products affected by the recall are on the company’s website at Customers with questions can contact Ameridose by calling (888) 820-0622 or by emailing the company at


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Social Media Mental Health Warnings Should Be Required To Protect Teens: U.S. Surgeon General
Social Media Mental Health Warnings Should Be Required To Protect Teens: U.S. Surgeon General (Posted today)

U.S. Surgeon General says social media platforms like Facebook, Instagram and Tiktok should carry label warnings, alerting parents that youth who use the platforms face an increased risk of mental health side effects.

Camp Lejeune Contaminated Water Lawsuits To Be Selected For Track 1 Bellwether Trials
Camp Lejeune Contaminated Water Lawsuits To Be Selected For Track 1 Bellwether Trials (Posted yesterday)

Lawyers will select 25 Camp Lejeune lawsuits involving kidney cancer, bladder cancer, leukemia, non-Hodgkin's lymphoma or Parkinson's disease from a group of 100 eligible cases, which will be prepared for a series of early test trials.